These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 25424783)
1. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Zhu F; Li J; Hu Y; Zhang X; Yang X; Zhao H; Wang J; Yang J; Xia G; Dai Q; Tang H; Suryakiran P; Datta SK; Descamps D; Bi D; Struyf F Hum Vaccin Immunother; 2014; 10(7):1795-806. PubMed ID: 25424785 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D; Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G; Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G; Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358 [TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Wheeler CM; Skinner SR; Del Rosario-Raymundo MR; Garland SM; Chatterjee A; Lazcano-Ponce E; Salmerón J; McNeil S; Stapleton JT; Bouchard C; Martens MG; Money DM; Quek SC; Romanowski B; Vallejos CS; Ter Harmsel B; Prilepskaya V; Fong KL; Kitchener H; Minkina G; Lim YKT; Stoney T; Chakhtoura N; Cruickshank ME; Savicheva A; da Silva DP; Ferguson M; Molijn AC; Quint WGV; Hardt K; Descamps D; Suryakiran PV; Karkada N; Geeraerts B; Dubin G; Struyf F; Lancet Infect Dis; 2016 Oct; 16(10):1154-1168. PubMed ID: 27373900 [TBL] [Abstract][Full Text] [Related]
11. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. McKeage K; Romanowski B Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Szarewski A; Poppe WA; Skinner SR; Wheeler CM; Paavonen J; Naud P; Salmeron J; Chow SN; Apter D; Kitchener H; Castellsagué X; Teixeira JC; Hedrick J; Jaisamrarn U; Limson G; Garland S; Romanowski B; Aoki FY; Schwarz TF; Bosch FX; Harper DM; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G; Int J Cancer; 2012 Jul; 131(1):106-16. PubMed ID: 21858807 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR; Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093 [TBL] [Abstract][Full Text] [Related]
15. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®). McKeage K; Romanowski B BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063 [TBL] [Abstract][Full Text] [Related]
17. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Garland SM; Paavonen J; Jaisamrarn U; Naud P; Salmerón J; Chow SN; Apter D; Castellsagué X; Teixeira JC; Skinner SR; Hedrick J; Limson G; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Del Rosario-Raymundo MR; Catteau G; Descamps D; Struyf F; Lehtinen M; Dubin G; Int J Cancer; 2016 Dec; 139(12):2812-2826. PubMed ID: 27541373 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F Cancer Med; 2017 Jan; 6(1):12-25. PubMed ID: 27998015 [TBL] [Abstract][Full Text] [Related]
19. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Kreimer AR; González P; Katki HA; Porras C; Schiffman M; Rodriguez AC; Solomon D; Jiménez S; Schiller JT; Lowy DR; van Doorn LJ; Struijk L; Quint W; Chen S; Wacholder S; Hildesheim A; Herrero R; Lancet Oncol; 2011 Sep; 12(9):862-70. PubMed ID: 21865087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]